Please ensure Javascript is enabled for purposes of website accessibility

A Drug That May Be Better Than Marijuana Sent This Company's Stock Soaring 196% in September

By Todd Campbell - Oct 4, 2017 at 6:31AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Marijuana can reduce seizures in epilepsy patients, but Zogenix's ZX008 might control seizures even better.

What happened

Shares of Zogenix, Inc(ZGNX) skyrocketed 196% higher in September after the company reported data from a study that suggested low-dose fenfluramine lowers the rate of seizures in Dravet syndrome patients by more than GW Pharmaceuticals' (GWPH) marijuana-based drug Epidiolex.

So what

Zogenix's ZX008 may soon offer new hope to patients living with a rare form of epilepsy called Dravet syndrome. 

A rocket soaring into space.


Dravet syndrome is an uncommon and debilitating form of childhood-onset epilepsy that's inadequately treated with existing anti-epileptic medications.

Because there's a big unmet need for new treatment options in the indication, GW Pharmaceuticals' shares rallied to all-time highs last year following news that its marijuana-based drug, Epidiolex, can lower monthly seizures by about 40%. Epidiolex is a purified formulation of cannabidiol (CBD), a common chemical found in marijuana.

Epidiolex's efficacy reinforces the long-held belief that marijuana strains that are high in cannabidiol (CBD) can help epilepsy patients, but data from Zogenix's low-dose fenfluramine (ZX008) trial suggests it may control seizures in tough-to-treat epilepsy even better than marijuana.

Patients taking 0.8 mg of ZX008 saw the number of their monthly seizures decline by an average 64% and median 72%. For perspective, people taking a placebo only saw a median 17.4% decline in monthly seizures. Only 2.5% of patients who took the placebo achieved a 75% or greater reduction in monthly seizures, while 45% of patients in the Zogenix study achieved that level of benefit. 

Now what

GW Pharmaceuticals has a headstart because its trials have already wrapped up and it plans to file for an FDA approval soon. That puts Epidiolex's potential launch sometime next year. 

Zogenix is still waiting for confirmatory data from a second phase 3 trial, and that data isn't expected until next year. That suggests that ZX008 might not hit the market until sometime in 2019, depending on the exact timing of its filing.

Initially, both drugs will target a limited patient population. However, each has the potential to see their use expand to more patients because, frankly, current antiepileptics inadequately control seizures for many patients. Since the market for epilepsy treatment is a big one, peak sales for these drugs could be in the nine figures.

Which drug will get prescribed the most? It depends on ZX008's second phase 3 trial results and doctors' views of the safety profiles of the two drugs. Stay tuned.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Zogenix, Inc. Stock Quote
Zogenix, Inc.
GW Pharmaceuticals plc Stock Quote
GW Pharmaceuticals plc

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.